Testimonies from the Trenches Series - Buprenorphine in Residential Treatment Settings (On-Demand)-2022-01-13 - AOAAM Webinar Slides

2022-01-13 - AOAAM Webinar Slides - Dr. McCormick

Pdf Summary

This document discusses the use of buprenorphine in the residential treatment setting for opioid use disorders. The objectives of the document include understanding the options for medicated assisted treatment (MAT), creating a framework for guiding patients to the appropriate MAT, and post discharge referrals. The document also discusses detox and induction of buprenorphine, including factors to consider such as recent history of use, physical exam, and comfort medications. It also examines the decision-making process for choosing buprenorphine, including factors such as involvement in a 12-step recovery program, history of overdoses, and mental health status. The document provides information on different forms of buprenorphine products, such as sublingual tabs, sublingual films, and injectable buprenorphine, and discusses dosage considerations, duration of treatment, and the weaning process. It also touches on the neurocognitive discussion regarding drug testing by employers and public perception of buprenorphine. The document concludes with a post-discharge plan that includes finding a good, like-minded doctor, involving family in the treatment process, and engaging in therapy and 12-step involvement. Finally, it provides some resources like ASAM and SAMSHA for further information.

Keywords

buprenorphine

residential treatment

MAT

detox

12-step recovery program

sublingual tabs

injectable buprenorphine

dosage considerations

weaning process

post-discharge plan